CEREGLIDE 92 Catheter for Ischemic Stroke
(SPLENDID Trial)

Recruiting in Palo Alto (17 mi)

+14 other locations

Michael Froehler, MD, PhD | Department ...

Dr. Ansaar T. Rai, MD | Morgantown, WV ...

Overseen ByBrian Jankowitz, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?The device is indicated for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease

Eligibility Criteria

This trial is for individuals who have recently experienced an acute ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of 6 or higher and a modified Rankin Scale (mRS) score of 2 or lower. They must understand the study and agree to participate. Pregnant individuals, those with short life expectancy, chronic occlusions, dementia, recent hemorrhage or mass effects on imaging are excluded.

Inclusion Criteria

Completed informed consent

I have been diagnosed with a stroke caused by a blood clot.

I can carry out all my usual duties without assistance.

+1 more

Exclusion Criteria

Known pregnancy

Life expectancy less than 90 days prior to stroke onset

I have a blood clot in the veins of my brain.

+6 more

Participant Groups

The CEREGLIDE 92 intermediate catheter is being tested for its safety and effectiveness in reopening blocked blood vessels in the brain during an acute ischemic stroke. The goal is to restore blood flow quickly to prevent further brain damage.

1Treatment groups

Experimental Treatment

Group I: Single ArmExperimental Treatment1 Intervention

Mechanical Thrombectomy